匹多莫德口服液治疗支气管哮喘患儿疗效观察

Clinical observation on the effect of pidotimod oral liquid on children with bronchial asthma

目的观察匹多莫德口服液对支气管哮喘患儿临床疗效。方法选取2014年8月至2016年8月深圳市南山区人民医院儿科收治住院的哮喘患儿120例为研究对象,随机分为观察组和对照组各60例。对照组患儿给予吸氧、止咳、祛痰、解痉、平喘、抗感染等常规对症治疗,观察组患儿在对照组治疗基础上加用匹多莫德口服液治疗,4周为1个疗程,共治疗3个疗程。观察患儿临床症状、体征变化及肺功能(第1秒用力呼气容积、用力肺活量、最大呼气流量)、免疫功能的改善和疗效情况。结果观察组总有效率为93.3%(56/60),显著高于对照组73.3%(44/60),差异有统计学意义(P<0.05)。观察组治疗后第1秒用力呼气容积、用力肺活量、最大呼气流量显著高于对照组,差异有统计学意义(P<0.05)。观察组治疗后CD3+、CD4+水平和CD4+/CD8+比值显著高于对照组,CD8+显著低于对照组,差异有统计学意义(P<0.05)。结论匹多莫德口服液治疗小儿支气管哮喘疗效显著,安全性较好,能够明显提高患儿免疫力,临床推广、应用价值更高。

ObjectiveTo observe the clinical effect of pidotimod oral liquid on children with bronchial asthma.MethodsA total of120children with asthma were included as the research subjects,and were randomly divided into two groups:the observation group(60cases)and the control group(60cases).The children in both groups were given conventional expectant treatment of oxygen inhalation,relieving cough,eliminating phlegm,and spasmolytic,antiasthmatic and anti infection therapy;the children in observation group was also treated with pidotimod oral liquid,four weeks as a course for3courses.Observe the clinical symptoms,changes in symptoms and lung function,immune function and the clinical effect.ResultsThe total effective rate of observation group was93.3%(56/60)significantly higher than that of control group(73.3%,44/60),the difference being statistical(P<0.05).After treatment,FEV1,FVC and maximal expiratory flow of observation group were significantly higher than those of control group,and there was statistical difference(P<0.05).The level of CD3+and CD4+and CD4+/CD8+ratio were significantly higher in observation group than in control group after treatment,while CD8+level was significantly lower,the difference being statistical(P<0.05).ConclusionPidotimod oral liquid has significant effect in treating children with bronchial asthma;it is safe and can significantly improve the children's immunity,which is worthy of clinical promotion.